189 related articles for article (PubMed ID: 23348900)
41. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract][Full Text] [Related]
42. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
44. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system.
Su MC; Yuan RH; Lin CY; Jeng YM
Mod Pathol; 2008 Nov; 21(11):1379-86. PubMed ID: 18552820
[TBL] [Abstract][Full Text] [Related]
45. Novel markers of squamous differentiation in the urinary bladder.
Huang W; Williamson SR; Rao Q; Lopez-Beltran A; Montironi R; Eble JN; Grignon DJ; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Hahn NM; Wang M; Koch MO; Cheng L
Hum Pathol; 2013 Oct; 44(10):1989-97. PubMed ID: 23806524
[TBL] [Abstract][Full Text] [Related]
46. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
Mohammed KH; Siddiqui MT; Cohen C
Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
[TBL] [Abstract][Full Text] [Related]
47. Deleted-in-colon-cancer protein expression in patients with adenocarcinoma of the urinary tract and a history of colorectal cancer.
Yossepowitch O; Koren R; Konichezki M; Livne PM; Baniel J
Urology; 2004 Dec; 64(6):1133-8. PubMed ID: 15596185
[TBL] [Abstract][Full Text] [Related]
48. GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall.
Akgul M; Humble R; Osme A; Yuce S; Kocak EN; Najafzadeh P; Sangoi A; Pattnaik N; Mishra S; Sharma S; Shaker N; Kaushal S; Baisakh M; Lightle AR; Balzer BL; Xiao GQ; MacLennan GT; Osunkoya AO; Parwani A; Cheng L; Bellizzi A; Mohanty SK
Diagn Pathol; 2022 Nov; 17(1):87. PubMed ID: 36320040
[TBL] [Abstract][Full Text] [Related]
49. Malignant glandular lesions and glandular differentiation in invasive/noninvasive urothelial carcinoma of the urinary bladder.
Behzatoğlu K
Ann Diagn Pathol; 2011 Dec; 15(6):422-6. PubMed ID: 21855380
[TBL] [Abstract][Full Text] [Related]
50. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB; Schaeffer DF
Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
[TBL] [Abstract][Full Text] [Related]
51. Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma.
Schwartz LE; Khani F; Bishop JA; Vang R; Epstein JI
Am J Surg Pathol; 2016 Jan; 40(1):27-35. PubMed ID: 26426382
[TBL] [Abstract][Full Text] [Related]
52. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
53. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
Almassi N; Whiting K; Toubaji A; Lenis AT; Jordan EJ; Won H; Regazzi AM; Chen YB; Gopalan A; Sirintrapun SJ; Fine SW; Tickoo SK; Ostrovnaya I; Pietzak EJ; Cha EK; Goh AC; Donahue TF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Teo MY; Funt SA; Rosenberg JE; Reuter VE; Bajorin DF; Solit DB; Al-Ahmadie H; Iyer G
JCO Precis Oncol; 2022 Jun; 6():e2100392. PubMed ID: 35731998
[TBL] [Abstract][Full Text] [Related]
54. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
[TBL] [Abstract][Full Text] [Related]
55. Flat urothelial carcinoma in situ of the bladder with glandular differentiation.
Lopez-Beltran A; Jimenez RE; Montironi R; Patriarca C; Blanca A; Menendez CL; Algaba F; Cheng L
Hum Pathol; 2011 Nov; 42(11):1653-9. PubMed ID: 21531007
[TBL] [Abstract][Full Text] [Related]
56. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
57. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract][Full Text] [Related]
58. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
59. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients.
Perrino CM; Eble J; Kao CS; Whaley RD; Cheng L; Idrees M; Hashemi-Sadraei N; Monn MF; Kaimakliotis HZ; Bandali E; Grignon D
Hum Pathol; 2019 Aug; 90():27-36. PubMed ID: 31054897
[TBL] [Abstract][Full Text] [Related]
60. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
